

Sebaceous Carcinoma of the Vulva: A Case Report and Review of the Literature

Hind Alharthi, Hala Alnuaim¹, Ohoud Aljarbou¹, Haitham Arabi²

Princess Nora Bint Abdul Rahman University, College of Medicine, ¹Department of Pathology and Laboratory Medicine, King Abdulaziz Medical City, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia

Access this article online

Website: www.avicennajmed.com

DOI: 10.4103/ajm.ajm_183_20

Quick Response Code:



ABSTRACT

Sebaceous carcinoma is a rare malignant cutaneous neoplasm that is most commonly arises in the ocular region. Although it can occur in extraocular sites, sebaceous carcinoma is rarely encountered in the vulva. The use of immunohistochemical staining is very crucial to exclude other differential diagnoses including primary cutaneous and metastatic neoplasms. Unlike ocular sebaceous carcinoma, little is known about the clinical behavior and the prognostic factors in vulvar sebaceous carcinoma. Herein, we present a case of vulvar sebaceous carcinoma in a 27-year-old female, who presented with a labial tumor with lung metastases. To the best of our knowledge, only 11 similar cases were previously reported in the literature.

Key words: Vulva, vulvar carcinoma, vulvar sebaceous carcinoma

INTRODUCTION

Carcinoma of the sebaceous glands is a rare malignant cutaneous neoplasm.^[1] The potential risk factors include female gender, Asian race, and previous exposure to head and neck radiation. Sebaceous carcinomas can be divided into two groups: ocular and extraocular. The latter is less common and can involve head and neck and genitals. Sebaceous carcinoma is an aggressive tumor that may spread to the local lymph nodes.^[1] Patients usually present with a gradually growing painless nodule.

Sebaceous carcinoma of the female genital tract is very uncommon. We are presenting an unusual case of sebaceous carcinoma of the vulva that metastasized to the lung.

CASE REPORT

A 27-year-old, Filipino lady presented to the obstetric and gynecological clinic with painful vaginal swelling for 4 weeks which increased in size over 2 weeks. She also complained

of painful micturition. The patient had no family history of any malignancy.

Pelvic examination revealed a 1 cm red tender firm lesion in the left labia majora. A punch biopsy was taken. Microscopically, the biopsy showed a high-grade neoplasm involving the dermis with focal ulceration of the overlying epidermis. The tumor was composed of lobules/nests of cells separated by fibrovascular stroma [Figure 1A]. The nuclei were large, with prominent nucleoli and scattered mitoses [Figure 1B and C]. Tumor nests focally exhibited comedo-type necrosis. Scattered cells showed sebaceous differentiation, manifested by finely vacuolated or foamy cytoplasm [Figure 1D].

By immunohistochemistry, the neoplastic cells were positive for EMA, BER-EP4 [Figure 1E and F], CK8/18,

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Cite this article as: Alharthi H, Alnuaim H, Aljarbou O, Arabi H. Sebaceous carcinoma of the vulva: a case report and review of the literature. *Avicenna J Med* 2021;11:49-53.

Address for correspondence: Dr. Haitham Arabi, Pathology and Laboratory Medicine MC-1122, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Kingdom of Saudi Arabia. E-mail: mharabi@hotmail.com.




Figure 1: The tumor is composed of lobules/nests of cells separated by a fibrovascular stroma. Comedo-type necrosis is present (A). Tumor cells have large nuclei with prominent nucleoli (B) and scattered mitoses (C). Scattered cells show sebaceous differentiation manifested by finely vacuolated or foamy cytoplasm (D). Tumor cells are positive EMA (E) and BER-EP4 (F) immunostains

and focally positive for CK20. They were negative for androgen receptor (AR), P16, S100, P63, CK5/6, CK7, and Pax-8. Ki-67 immunostain showed a high proliferation index (approximately 50–60%). Based on the morphology and the immunoprofile, the diagnosis of vulvar sebaceous carcinoma was favored.

An endometrial biopsy was performed and showed complex endometrial hyperplasia without atypia, associated with extensive squamous metaplasia (morules) and chronic endometritis. A cervical Pap smear was also obtained which yielded normal findings.

The subsequent radiological work-up, including abdomen and pelvis computed tomography (CT) scan and magnetic resonance imaging, revealed a left adnexal solid mass measuring 8.2 cm × 6.8 cm × 6.6 cm associated with retroperitoneal lymphadenopathy. These findings were

worrisome for malignancy. A chest CT scan showed multiple bilateral suspicious lung nodules.

Positron emission tomography (PET)/CT was performed and it demonstrated an intensely hypermetabolic mass extending from the vulva through the vagina which was consistent with the biopsy-proven malignancy. Another hypermetabolic pelvic mass abutting the uterus is also noted. Multiple hypermetabolic lung nodules were observed. A left ischium lesion, as well as para-aortic and inguinal lymph nodes, was suspicious of metastasis.

CT-guided core biopsy of the lung nodules was obtained and it revealed a small focus of metastatic poorly differentiated carcinoma, morphologically, and immunohistochemically consistent with the patient's previous diagnosis of labial sebaceous carcinoma.

Table 1: Clinicopathological features of published cases of vulvar sebaceous carcinoma

Author	Age	Site	Size	Appearance	Duration of symptoms	Management	Metastasis	Follow-up
Present case	27	Left labia majora	1 cm (4.3 x 3 x 4.5 cm) by MRI	Red swelling	4 weeks	Chemotherapy and immunotherapy	Lung (confirmed by biopsy) Left ischium lesion, para-aortic and inguinal lymph nodes and possibly left ovary (by PET/CT) Right inguinal lymph node	CT scan which showed a partial response in the lungs and stable disease in the abdomen and pelvis. Tumor resisted chemo and immunotherapy. Died of disease after 8 months of follow-up.
Thakur et al. ^[13]	55	Right labia majora and minora	Two lesions 2.5 x 2 cm and 1 x 1.5 cm	Ulcerative nodule	4 months	Radiotherapy	No metastasis	8 months of follow-up, alive, no evidence of recurrence
Sullivan et al. ^[14]	76	Vulva, not otherwise specified.	0.5 cm	Visible papule	Not stated	Resection and left inguinal lymphadenectomy	No metastasis	10 months of follow-up, alive, no evidence of recurrence
Yam et al. ^[15]	64	Right labia minora	2 x 1.5 cm	Exophytic tumor	12 months	Excision	No metastasis	Regular follow-ups, alive, no evidence of recurrence.
Pusiol et al. ^[6]	51	Left labia majora	2.5 x 1.5 cm	Exophytic red and white tumor	6 months	Hemivulvectomy	No metastasis	18 months of follow-up, alive, no evidence of recurrence
Khan et al. ^[2]	49	Right labia majora	0.5 cm	Papilloma	Not stated	Excision of the right vulva, bilateral inguinal lymphadenectomy, and external beam radiotherapy to both groins	Left inguinal lymph node	Recurrence after 7 months. Excision was performed followed by palliative chemotherapy
Escalona et al. ^[16]	76	Right labia majora	4 cm x 3 cm	Red white tumor and small papule	4 months	Left radical hemivulvectomy	No metastasis	12 months of follow-up, alive, no evidence of recurrence
Carlson et al. ^[12]	46	Left labia majora	Not stated	Cyst	Not stated	Left radical hemivulvectomy with left inguinal lymphadenectomy	No metastasis	31 months of follow-up, alive, no evidence of recurrence
Kawamoto et al. ^[17]	78	Left labia minora	2.5 x 1.5 cm	Yellow white nodule	6 months	Simple vulvectomy, dissection of the left inguinal lymph nodes, and radiation therapy for the left inguinal area	Left inguinal lymph node	17 months of follow-up, alive, no evidence of recurrence
Jacobs et al. ^[18]	89	Left labia minora	Two lesion: 3.0 x 1.4 cm and 1.0 x 0.8 cm.	Pink white plaque	1 year	Left radical hemivulvectomy	No metastasis	Not stated
Ikuse et al. ^[19]	75	Labia majora	Not available	Red ulcer	2 years	Not available	Lung	Dead
Rulon et al. ^[7]	31	Left labia minora	2.0 cm x 1.1 cm	Raw yellow slightly indurated plaque	6 months	Excision	Not stated	13 years and 7 months of follow-up, alive, no evidence of recurrence

Based on the radiological and histopathological findings, the patient was diagnosed with stage IV sebaceous carcinoma. She was started on a chemotherapy regimen of Carboplatin and Paclitaxel.

The patient completed 8 weeks of chemotherapy. A follow-up CT scan showed a partial response in the lungs and stable disease in the abdomen and pelvis. Next-generation sequencing performed on the vulvar biopsy revealed a microsatellite stable tumor with low mutational burden. There were no official druggable mutations; however, PIK3CA mutation was detected. Accordingly, Everolimus was offered as an additional treatment. Due to her pain, she was given 20 Gy in five fractions to the left lytic ischial lesion. Despite the optimal medical treatment, her disease progressed and she subsequently passed away 8 months after the initial diagnosis.

DISCUSSION

Sebaceous carcinoma is a rare, yet aggressive, cutaneous appendageal tumor that most commonly arises in the periocular area. Rarely, sebaceous carcinoma occurs in extraocular sites such as the face, scalp, trunk, limbs, and external genitalia.^[2]

Sebaceous carcinoma may occur sporadically or in association with a genetic predisposition to Muir–Torre syndrome, an autosomal dominant disease characterized by the concurrent or sequential development of sebaceous gland tumors and at least one internal malignancy.^[3,4] Muir–Torre syndrome is caused by germline mutations in the DNA mismatch repair (MMR) genes and is considered a phenotypic variant of hereditary nonpolyposis colorectal carcinoma syndrome (HNPCC, Lynch syndrome).^[3] Internal malignancies most frequently associated with this syndrome include colorectal, endometrial, ovarian, and urothelial carcinomas.^[5,6]

Sebaceous carcinoma of the vulva is exceptionally rare with only 11 cases reported previously [Table 1]. It was first reported in 1974 by Rulon *et al.*^[7] The median age at the time of the diagnosis, including the present case, is 60 years. The tumor size varies from 0.5 cm to 4.0 cm in maximum dimension. The clinical appearance of the lesion is extremely variable with no specific shape or color.

Due to its rarity, other differential diagnoses must be excluded including primary cutaneous and metastatic neoplasms. These include basal cell carcinoma with sebaceous differentiation, squamous cell carcinoma with clear cell features, melanoma, and metastatic carcinoma

from other sites (i.e. metastatic serous carcinoma in our case). The use of ancillary studies can help in differentiating between these entities. Like in our case, the negative staining for CK5/6 and P63 rules out squamous cell carcinoma. Both sebaceous carcinoma and basal cell carcinoma can express BerEp4; however, these two tumors can be differentiated using EMA immunostain which is usually positive in sebaceous carcinoma and negative in basal cell carcinoma. S100 immunostain would be helpful in melanocytic tumors. Metastatic serous carcinoma can be excluded by the negative staining for CK7, P16, and PAX-8.

The overall clinical characteristics of the previously reported cases are favorable. However, unlike ocular sebaceous carcinoma, little is known about prognostic factors in vulvar sebaceous carcinoma. Older age, higher-grade tumors, and distant and/or inguinal lymph node metastasis have been described as poor prognostic factors.^[8,9] Of the 12 cases, metastasis to inguinal lymph nodes was observed in four cases, while two cases, including our patient, have lung involvement at the time of presentation. Additionally, it is reported that the loss of AR expression (like in our case) is considered as an adverse prognostic factor in sebaceous carcinoma and it may represent a lack of differentiation or dedifferentiation of the tumor.^[10]

Due to the limited number of reported cases, the optimal treatment of sebaceous carcinoma of the vulva has not been well established.^[8] Although there is limited supportive data, surgical excision with or without lymphadenectomy appears to be the appropriate first intervention with a goal of complete excision of disease.^[2,9,11] Cases that showed metastasis were either followed by chemotherapy, radiotherapy, or both. Radiotherapy alone was used successfully in some cases of recurrence and inguinal lymph node metastases.^[8,12]

In summary, sebaceous carcinoma of the vulva is an exceptionally uncommon neoplasm. Due to its rarity, the clinical behavior, prognosis, and optimal treatment are yet to be further assessed.

Financial support and sponsorship
Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Dasgupta T, Wilson LD, Yu JB. A retrospective review of 1349 cases of sebaceous carcinoma. *Cancer* 2009;115:158-65.
2. Khan Z, Misra G, Fiander AN, Dallimore NS. Sebaceous carcinoma of the vulva. *Bjog* 2003;110:227-8.

3. Gay JT, Gross GP. Muir-Torre Syndrome. Treasure Island (FL): StatPearls; 2019.
4. Harwood CA, Swale VJ, Bataille VA, Quinn AG, Ghali L, Patel SV, *et al.* An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients. *J Invest Dermatol* 2001;116:246-53.
5. Cohen PR, Kohn SR, Davis DA, Kurzrock R. Muir-Torre syndrome. *Dermatol Clin* 1995;13:79-89.
6. John AM, Schwartz RA. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management. *J Am Acad Dermatol* 2016;74:558-66.
7. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. *Cancer* 1974;33:82-102.
8. Pusiol T, Morichetti D, Zorzi MG. Sebaceous carcinoma of the vulva: Critical approach to grading and review of the literature. *Pathologica* 2011;103:64-7.
9. Woelber L, Mahner S, Voelker K, Eulenburg CZ, Giesecking F, Choschzick M, *et al.* Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. *Anticancer Res* 2009;29:545-52.
10. Na HY, Choe JY, Shin SA, Choung HK, Oh S, Chung JH, *et al.* Proposal of a provisional classification of sebaceous carcinoma based on hormone receptor expression and HER2 status. *Am J Surg Pathol* 2016;40:1622-30.
11. Audisio RA, Lodeville D, Quagliuolo V, Clemente C. Sebaceous carcinoma arising from the eyelid and from extra-ocular sites. *Tumori* 1987;73:531-5.
12. Carlson JW, McGlennen RC, Gomez R, Longbella C, Carter J, Carson LF. Sebaceous carcinoma of the vulva: A case report and review of the literature. *Gynecol Oncol* 1996;60:489-91.
13. Thakur BK, Verma S, Khonglah Y, Jitani A. Multifocal sebaceous carcinoma of the vulva. *Indian J Dermatol Venereol Leprol* 2017;83:221-4.
14. Sullivan SA, Tran AQ, O'Connor S, Gehrig PA. Sebaceous carcinoma of the vulva: A case report and review of the literature. *Gynecol Oncol Rep* 2016;18:40-1.
15. Yam P, Namuduri R, Chia Y, Kuei T. Sebaceous carcinoma of the vulva – A rare tumor of vulva. *Int J Gynecol Obstet* 2012;119S3:S531-867.
16. Escalonilla P, Grilli R, Cañamero M, Soriano ML, Fariña MC, Manzarbeitia F, *et al.* Sebaceous carcinoma of the vulva. *Am J Dermatopathol* 1999;21:468-72.
17. Kawamoto M, Fukuda Y, Kamoi S, Sugisaki Y, Yamanaka N. Sebaceous carcinoma of the vulva. *Pathol Int* 1995;45:767-73.
18. Jacobs DM, Sandles LG, Leboit PE. Sebaceous carcinoma arising from Bowen's disease of the vulva. *Arch Dermatol* 1986;122:1191-3.
19. Ikuse S, Jinbou A, Matsushima I. A case of sebaceous carcinoma. *Jpn J Dermatol* 1976;86:783.